SAVARA INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.075 USD | +1.70% |
|
+8.55% | +8.09% |
Presentation Operator MessageOperator (Operator)Welcome to the Savara conference call. [Operat...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Companyâs lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.99
USD
Average target price
8.786
USD
Spread / Average Target
+76.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.09% | 690M | |
| +3.18% | 108B | |
| +10.32% | 105B | |
| +1.57% | 23.46B | |
| -13.05% | 21.72B | |
| -7.05% | 18.64B | |
| -37.64% | 17.45B | |
| -6.89% | 17.19B | |
| +5.78% | 13.99B | |
| +36.43% | 12.53B |
- Stock Market
- Equities
- SVRA Stock
- News Savara Inc.
- Transcript : Savara Inc., Q1 2019 Earnings Call, May 09, 2019